Satraplatin, also known as JM216 and BMS182751, is an orally available antineoplastic platinum(IV) complex, that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.